8-K: Pulse Biosciences Advances AF Ablation, Reports Q4 & FY25 Results

Pulse Biosciences announced significant clinical progress in its atrial fibrillation ablation programs and reported its fourth quarter and full year 2025 financial results, showing increased revenue but also higher net losses.

Summary

• Pulse Biosciences achieved notable milestones in 2025 across its market development programs, advancing its nsPFA platform into late-stage clinical development for atrial fibrillation (AF) in both electrophysiology and cardiac surgery.
• The company received FDA IDE approvals to initiate pivotal studies for both endocardial catheter and surgical AF ablation systems.
• The first-in-human feasibility study for the nPulse Cardiac Catheter System demonstrated 100% procedural success at 6 months and 96% procedural success at one year for evaluable patients in treating paroxysmal AF.
• A highly controlled commercial launch of the nPulse Vybrance percutaneous electrode system for soft tissue ablation generated $264 thousand in revenue during Q4 2025, contributing to a full-year revenue of $350 thousand.
• GAAP net loss for the full year 2025 was ($72.8) million, an increase from ($53.6) million in the prior year, primarily due to expanding organizational expenses for clinical trials and commercialization.
• Cash and cash equivalents decreased to $80.7 million as of December 31, 2025, from $118.0 million at the end of 2024, with $14.8 million used in operating activities during Q4 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, driven by strong clinical progress and FDA approvals for pivotal studies, which de-risk the technology's path to market. However, the significant increase in net losses and cash burn for the full year, coupled with a declining cash balance, introduces financial caution.

Positives

• Achieved 100% procedural success at 6 months and 96% at one year in the first-in-human feasibility study for endocardial catheter AF ablation.
• Received FDA approval in Q4 2025 to commence a pivotal IDE study for paroxysmal atrial fibrillation with the nPulse Cardiac Catheter System.
• Continued enrollment in the NANOCLAMP AF IDE pivotal study for surgical AF ablation, which is the first PFA study approved by the FDA for a surgical cardiac ablation device.
• Generated $264 thousand in revenue from a highly controlled commercial launch of the nPulse Vybrance percutaneous electrode system in Q4 2025, with full year revenue reaching $350 thousand.
• Initiated a research collaboration with University of Texas MD Anderson Cancer Center to evaluate nsPFA for benign and malignant thyroid tumors.
• GAAP costs and expenses for Q4 2025 decreased by $1.7 million to $18.5 million compared to $20.3 million in the prior year period, driven by lower non-recurring legal and severance costs.

Negatives

• GAAP net loss for the full year 2025 increased to ($72.8) million from ($53.6) million in 2024.
• Non-GAAP net loss for the full year 2025 increased to ($50.8) million from ($36.9) million in 2024.
• Total GAAP costs and expenses for the full year 2025 increased by $21.0 million to $77.3 million, primarily due to expanding operations for clinical trials and commercialization.
• Cash and cash equivalents declined to $80.7 million as of December 31, 2025, from $118.0 million as of December 31, 2024.
• Cash used in operating activities in Q4 2025 increased to $14.8 million, compared to $9.1 million in the same period of the prior year.

Risks

• The effectiveness of the nPulse technology to non-thermally clear cells while sparing adjacent noncellular tissue may not be fully realized.
• Potential market opportunities for nsPFA in treating AF or benign thyroid nodules may not grow as anticipated.
• Early clinical successes may not be predictive of the safety and effectiveness of any medical device, such as the nPulse Cardiac Surgical System.
• Future clinical and regulatory initiatives, including FDA approval of pending IDE submissions, may not proceed as expected.
• The nsPFA technology may not become a disruptive, superior, and durable treatment option for atrial fibrillation or other medical conditions.
• Actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and assumptions beyond the company's control.

Future Outlook

The company's focus in 2026 is on clinical trial execution, including completing pivotal enrollment in both cardiac programs for atrial fibrillation. It also plans to complete and expand enrollment in the PRECISE-BTN study for benign thyroid nodules in the coming quarters.

Management Comments

• "2025 was a highly productive year for Pulse Biosciences as we achieved notable milestones in each of our market development programs."
• "Most importantly, we have advanced our nsPFA platform into late-stage clinical development to treat atrial fibrillation in both electrophysiology and cardiac surgery, receiving FDA IDE approvals to initiate both pivotal studies."
• "I am thrilled in particular with the compelling clinical evidence being developed by our programs, especially the best-in-class procedural success rates treating paroxysmal AF from our large feasibility study."
• "Our focus in 2026 is on clinical trial execution, including completing pivotal enrollment in both cardiac programs."

Industry Context

StockSavvy.ai notes that Pulse Biosciences is making significant strides in the rapidly evolving field of Pulsed Field Ablation (PFA) for cardiac arrhythmias, particularly atrial fibrillation. The FDA IDE approvals for pivotal studies position the company to potentially become a key player in this innovative, non-thermal ablation technology, which is gaining traction as an alternative to traditional radiofrequency or cryoablation methods. The expansion into soft tissue ablation, including thyroid nodules, also indicates a broader application strategy for its nsPFA technology beyond cardiology.

Comparison to Industry Standards

• The company claims "best-in-class procedural success rates treating paroxysmal AF from our large feasibility study" with 100% procedural success at 6 months and 96% at one year for evaluable patients. However, specific comparable companies, projects, or detailed benchmarks from competitors are not provided in the filing to substantiate this claim directly.

Stakeholder Impact

• Shareholders: Potential for long-term value creation from successful clinical trials and commercialization, but also risk of dilution due to ongoing cash burn and potential future capital raises.
• Patients: Potential for new, effective, and 'best-in-class' treatment options for atrial fibrillation and benign thyroid nodules.
• Employees: Expanding organization to support clinical trials and commercialization indicates job growth and stability.
• Regulatory Authorities: Continued engagement with the FDA through IDE studies and approvals.

Next Steps

• Enroll the first patient in the pivotal IDE study for the treatment of paroxysmal atrial fibrillation with the nPulse Cardiac Catheter System in the next few months.
• Complete patient enrollment in the NANOCLAMP AF IDE pivotal study for surgical AF ablation in 2026.
• Complete enrollment of 50 patients in the PRECISE-BTN study for benign thyroid nodules in the next few months.
• Expand enrollment in the PRECISE-BTN study to 100 patients over the ensuing two quarters.
• Enroll the last patient in the pivotal IDE study for endocardial catheter AF ablation in Q4 2026.

Key Dates

Recommendation

Pulse Biosciences demonstrates strong clinical progress with its nsPFA technology, particularly in AF ablation, securing FDA IDE approvals and reporting high procedural success rates. This indicates significant long-term potential for a disruptive medical technology. However, this progress comes at a substantial financial cost, with increasing net losses and significant cash burn for the full year. The company's cash position is declining, suggesting future capital needs. While the clinical upside is considerable, the current financial trajectory warrants a cautious 'hold' stance, balancing the promising technology against the high operational costs and financial risks.

Keywords

Pulse Biosciences, PLSE, nsPFA, Nanosecond Pulsed Field Ablation, atrial fibrillation, AF ablation, cardiac catheter, surgical ablation, FDA IDE approval, clinical trials, benign thyroid nodules, medical device, financial results, biotech, electrophysiology